April 17, 2026

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

The ASCO Post

April 03, 2026

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individ...

The ASCO Post

April 03, 2026

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individ...

The ASCO Post

March 24, 2026

SIOG 2025: Celebrating 25 Years of Leadership in Geriatric Oncology

The 25th Annual Conference of the International Society of Geriatric Oncology (SIOG) convened in Ghent, Belgium, from November 20 to 22, 2025, marking a quarter-century of international collaboration ...

The ASCO Post

March 24, 2026

Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer

A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at th...

The ASCO Post

March 05, 2026

How AI Is Ushering in a New Era in Cancer Care

On October 30, 2025, Google Cloud held its second annual Cancer AI Symposium to explore how artificial intelligence (AI) is advancing cancer research, diagnosis, and treatment, in unparalleled ways. H...

The ASCO Post

February 27, 2026

United in Care at JADPRO Live 2025

Jadpro

February 24, 2026

Introducing ASCO AI in Oncology

In February, ASCO and Conexiant launched ASCO AI in Oncology (ascoai.org), a digital platform dedicated to understanding how artificial intelligence (AI) is impacting cancer care.

The ASCO Post

February 11, 2026

Highlights From the 2025 ASH Annual Meeting & Exposition

At this year’s American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, we had the opportunity to navigate both manned and unmanned traffic, contend with temperamental weather,...

The ASCO Post

January 07, 2026

AACR 2025: Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource-Limited Settings

Researchers explored whether artificial intelligence (AI) models pretrained on vast data sets may outperform standard baseline models in identifying nonmelanoma skin cancers, according to findings pre...

The ASCO Post